The Potential Effect of Metformin on Cancer: An Umbrella Review
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background: Metformin has been reported to possess anti-cancer properties in addition to glucose-lowering activity and numerous systematic reviews and meta-analyses have studied the association between metformin use and cancer incidence or survival outcomes. We performed an umbrella review to assess the robustness of these associations to facilitate proper interpretation of these results to inform clinical and policy decisions. Methods: We searched PubMed and Embase systematic reviews and meta-analyses investigating the effect of metformin use on cancer incidence or survival outcomes published from inception to September 2, 2018. We estimated the summary effect size, the 95% CI, and the 95% prediction interval, heterogeneity, evidence of small-study effects and evidence of excess significance bias. Results: We included 21 systematic reviews and meta-analyses covering 11 major anatomical sites and 33 associations. There was strong evidence for the association between metformin use and decreased pancreatic cancer incidence. The association between metformin use and improved colorectal cancer overall survival (OS) was supported by highly suggestive evidence. Seven associations (all cancer incidence, all cancer OS, breast cancer OS, colorectal cancer incidence, liver cancer incidence, lung cancer OS, and pancreatic cancer OS) presented only suggestive evidence. The remaining 24 associations were supported by weak or not-suggestive evidence. Conclusions: Associations between metformin use and pancreatic cancer incidence or colorectal cancer OS are supported by strong or highly suggestive evidence, respectively. However, these results should be interpreted with caution due to the poor methodological quality of the systematic reviews and meta-analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“Estimation of Prediction Intervals Ninety five percentage prediction intervals (PI) for the summary random effect estimates were calculated to further interpret interstudy heterogeneity and represent the prediction of the effect in an individual-study setting (15).”
MethodRyan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348 · cited 1×
“However, just 10–20% of the patients are eligible for surgical treatment because of the late diagnosis (42).”
BackgroundUncertainty in heterogeneity estimates in meta-analyses
Ioannidis, J. P. A., Patsopoulos, N. A., & Evangelou, E. (2007) · BMJ · doi:10.1136/bmj.39343.408449.80 · Cited by 1,254 · cited 1×
“The 95% CI of I2 was calculated to assess the uncertainty around heterogeneity estimates (14).”
BackgroundNew Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“According to another study, metformin likely has an inhibitory effect on tumor progression in patients with T2DM, which can reduce the risk of tumor and tumor-related mortality of patients, improving their survival rate (9).”
BackgroundDowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Adiposity and cancer at major anatomical sites: umbrella review of the literature
Kyrgiou, M., Kalliala, I., Markozannes, G., Gunter, M. J., Paraskevaidis, E., Gabra, H., Martin-Hirsch, P., & Tsilidis, K. K. (2017) · BMJ · doi:10.1136/bmj.j477 · Cited by 803
An exploratory test for an excess of significant findings
Ioannidis, J. P., & Trikalinos, T. A. (2007) · Clinical Trials · doi:10.1177/1740774507079441 · Cited by 751 · cited 1×
“05) was different from the expected number of studies (E) with statistically significant results (17).”
ResultCancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Elgendy, M., Cirò, M., Hosseini, A., Weiszmann, J., Mazzarella, L., Ferrari, E., Cazzoli, R., Curigliano, G., DeCensi, A., Bonanni, B., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.007 · Cited by 299 · cited 1×
“(64), found that intermittent fasting in combination with metformin can inhibit the glycolysis and oxidative phosphorylation of tumor cells, namely the drug showing the best antitumor effect with low blood glucose level.”
BackgroundClarke, P. M., Gray, A. M., Briggs, A., Stevens, R. J., Matthews, D. R., Holman, R. R., & (UKPDS), O. B. O. T. U. P. D. S. (2005) · Diabetologia · doi:10.1007/s00125-005-1717-3 · Cited by 155 · cited 1×
“In 2005, Scottish researchers found that diabetic patients taking metformin had a lower risk of cancer, indicating that metformin may possess anti-tumor abilities (8).”
BackgroundZhuang, Y., Chan, D. K., Haugrud, A. B., & Miskimins, W. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108444 · Cited by 149 · cited 1×
“(65) also found that low glucose can enhance the toxicity of metformin in breast and ovarian cancer cells and reduce the intracellular ATP level.”
BackgroundTang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0936 · Cited by 117 · cited 1×
“(24) Breast cancer overall survival +++ + – – + – + +”
Synthesis of observational studies should consider credibility ceilings
Salanti, G., & Ioannidis, J. P. A. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.05.014 · Cited by 108 · cited 1×
“10% Credibility Ceiling Credibility ceiling analyses were performed to account for the innate methodological limitations of observational studies (18).”
BackgroundChu, D., Wu, J., Wang, K., Zhao, M., Wang, C., Li, L., & Guo, R. (2018) · BMC Cancer · doi:10.1186/s12885-018-4334-5 · Cited by 90 · cited 1×
“(30) Endometrial cancer – + + – – – – –”
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017) · Medicine · doi:10.1097/md.0000000000006888 · Cited by 89
Graff, S. K., Mario, F. M., Ziegelmann, P., & Spritzer, P. M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12787 · Cited by 63
He, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M. (2016) · Medicine · doi:10.1097/md.0000000000002749 · Cited by 59 · cited 1×
“(27) Colorectal cancer ++ + + + – – – –”
Hu, J., Chen, J.-B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., Liu, L.-F., Chen, H.-Q., & Zu, X.-B. (2018) · Medicine · doi:10.1097/md.0000000000011596 · Cited by 56 · cited 2×
“(23) Bladder cancer overall survival – – – – – – + –”
BackgroundThe impact of metformin use on survival in kidney cancer patients with diabetes: A meta-analysis
Li, Y., Hu, L., Xia, Q., Yuan, Y., & Mi, Y. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1548-4 · Cited by 38
Du, L., Wang, M., Kang, Y., Li, B., Guo, M., Cheng, Z., & Bi, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14688 · Cited by 32 · cited 1×
“(28) Colorectal cancer overall survival +++ + + – + – – +”
Xin, W.-X., Fang, L., Fang, Q.-L., Zheng, X.-W., Ding, H.-Y., & Huang, P. (2018) · Medicine · doi:10.1097/md.0000000000010035 · Cited by 18
Cited by
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
“incidence of gastrological cancer in patients with diabetes [59,60].”
BackgroundRepurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Hu, J., Chen, J.-B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., Liu, L.-F., Chen, H.-Q., & Zu, X.-B. (2018) · Medicine · doi:10.1097/md.0000000000011596 · Cited by 56
Metadata
- Authors
- Yu, H., Zhong, X., Gao, P., Shi, J., Wu, Z., Guo, Z., Wang, Z., & Song, Y.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-09-18
- Volume
- 10
- Pages
- 617-617
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2971332774
- Cited by
- 135
- References
- 26
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.